After a half century spent waging war on drugs, Americans seem ready to sue for peace. The 2020 elections brought plenty of proof that voters have leapt ahead of politicians in recognizing both the failures of the drug war and the potential of certain illicit drugs as powerful tools for healing.
Today, a Google turn ups the number for the Psychedelic Peer Support Line, sponsored by Fireside Project, launched in April as a one-year pilot offering limited hours Thursdays through Mondays. The support line, which can be reached by texting or calling 62-FIRESIDE (623-473-7433), was envisioned by former lawyer Joshua White in the early months of the pandemic, when the possibility of widespread psychedelic healing was the one thing giving him hope.
A new study by researchers at Yale University has shown that a single dose of psilocybin given to mice prompted an immediate and long-lasting increase in connections between neurons. Psilocybin is a naturally occurring compound found in magic mushrooms and has been touted as a potential treatment for depression in recent years. However, the mechanics of exactly how psilocybin works in the brain and how long beneficial results might last is still unclear.
Psilocybin, a psychedelic compound that can be derived from over 200 species of mushroom, can remodel connections in the mouse brain. That is the conclusion of a new study that examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.
Funded in part by Tim Ferriss, the Project on Psychedelics Law and Regulation will tackle the many unanswered legal questions facing psychedelic-assisted therapy.
This First Person article is the experience of Julian Uzielli, an associate producer with CBC Radio's Podcast Playlist. Facebook Twitter Pinterest Reddit LinkedIn Email Julian Uzielli says ketamine therapy has helped his chronic depression. Now, clinics are opening across Canada.
Field Trip Medical Director Dr. Michael Verbora & Executive Chairman Ronan Levy sit down with Nuvo Magazine to examine the current landscape of psychedelic healthcare, with an emphasis on our method of healing and the legalities of psilocybin.
The COVID-19 pandemic has amplified the spiraling mental health crisis in Canada. Here to talk about how psychedelic drug therapy can help is psychotherapist Dr. Mike Dow.
The former heavyweight champion says psychedelics would have helped him with his mental health during his career. Some scientists and companies agree.
Psychedelic therapy company Field Trip Health is looking to go public on the Nasdaq. Executive chair and co-founder Ronan Levy and former Senate Majority Leader Tom Daschle join ‘Squawk on the Street’ to make the case for investing in these therapies, the drugs involved and more.
One of the consequences of the pandemic is the dramatic growth of Telehealth and Telemedicine. But how can doctors and providers best care for their patients when they are not physically in front of them? What do doctors wish patients knew in order to make sure they are getting the best results even though they are not actually in the office? How can Telehealth approximate and even improve upon the healthcare that traditional doctors’ visits can provide?
A bill to legalize possession of psychedelics in California was approved by the California Senate on Tuesday. The legislation, sponsored by Sen. Scott Wiener (D), which previously cleared three committees, passed 21-16 on the floor.
Field Trip Health, Inc., a Toronto-based psychedelic-assisted therapy and drug development company, announced this month that former U.S. Senator-turned-lobbyist Tom Daschle will serve as a special advisor to the company. “Senator Daschle has participated in the development and debate of almost every major public policy issue of the last three decades and is a pre-eminent expert on health policy reform,” Joseph del Moral, co-founder and chief executive officer of Field Trip, said in a press release.
Lamar Odom Re/Born follows the former NBA superstar’s journey to break his addiction and anxiety with groundbreaking psychedelic medicines. Director Mike “Zappy” Zapolin, who is known as a psychedelic concierge, gives Lamar a psychedelic intervention using ketamine and ibogaine, along with a daily practice of meditation and breathing.
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities. Field Trip, which launched in 2019 in Toronto and began opening clinics across North America in 2020, offers patients what is currently the only psychedelic drug with Food and Drug Administration approval for prescription: the anesthetic ketamine.
Ketamine assisted psychotherapy is now approved for use in Canada, so yes, it is safe. Ketamine is the only psychedelic approved in Canada for use in treatment-resistant depression, though it’s been around since the 50’s. It’s a super fast-working therapy that has shown significant improvement in patients in just 24 hours! It can also be co-prescribed with other antidepressants for a more profound effect.
Medical scientists have caught on to the fact that cannabinoids help fight unwanted inflammation that contributes to many diseases. But the next anti-inflammatory wonder drug could come from an even more unexpected source: psychedelics.
One company pioneering the ketamine-assisted psychotherapy movement across North America is the psychedelic pioneers at Field Trip Health. They have opened several clinics across Canada and North America that, unlike other ketamine clinics, incorporate compassionate and comprehensive psychotherapy into the process. This guide explores their cutting-edge ketamine-assisted psychotherapy program for prospective clients and psychedelic enthusiasts alike.
It’s no surprise people are turning to psychedelics for therapy. There’s a mental health crisis due to the pandemic, and therapy is expensive and not an option for many. Research is showing some incredible results with psychedelic-assisted therapy for an array of conditions and disorders. There's now an app for that.
Psychedelic drugs are helping people across Canada improve their mental health. Despite what your high school health teacher might have told you, a dose of ketamine, LSD or psilocybin (better known as magic mushrooms) – when administered in a controlled setting by a trained medical professional – can be highly effective in treating conditions like PTSD and depression.
“As a food, mushrooms have a lot of things going for them in terms of their nutritional value,” said Joshua Lambert, a co-director of the Center for Plant and Mushroom Foods for Health at the Penn State College for Agricultural Sciences. “But one of the things we’re looking into are the other compounds that mushrooms and other plants have that may have significant health benefits.”
Mike Dow, host of TLC's 'Freaky Eaters,' has joined Field Trip Health, which describes ketamine as a protocol "designed to help those suffering from treatment-resistant depression, generalized anxiety disorder and trauma."
A recent study found that microdosing psychedelic drugs had beneficial psychological effects – but so did a placebo. That might seem like a dose of cold water for this promising area of mental health treatment, but DLSPH Adjunct Prof. Dr. Dominique Morisano, Chief Psychologist at Field Trip Health, sees it differently.
The most exciting aspect of this trial is a sense that we are on the verge of a paradigm shift in mental healthcare linked to an improved understanding of the origins of depression, and how we can most effectively treat it. In my view, this shift will take us away from an outdated and myopic “drug-alone” perspective that has dominated psychiatry for several decades, and towards a multi-level “biopsychosocial” model.
It’s been almost 80 years since that fateful first acid trip but it looks as if Hofmann’s “problem child” might be getting past the bumpy road stage and growing up to face a promising future. Which makes this Bicycle Day one of LSD’s best birthdays ever. At least so far.
To manage her stress and fears, Andrea Bird -- who is suffering from terminal cancer -- uses psychedelics, which are seeing a sudden re-emergence in Canada as a possible treatment for mental health conditions such as anxiety and depression. The 60-year-old Canadian was diagnosed with breast cancer in 2012. Despite aggressive treatment, the disease returned five years later, spreading to her lungs, bones and brain.
2020 was a lot on our brains. Life can also be a lot on our brains. How do we cope with all of the trauma, anxiety, and baggage so that we’re not weighed down? A few options may have come to mind, but it’s unlikely that you’ve ever thought about anything like this! Introducing Field Trip Health, the groundbreaking company redefining mental well-being and consciousness through psychedelic-enhanced psychotherapy, recently opened its doors to Los Angelenos. We’re excited to share the news of Field Trip Health’s Los Angeles clinic opening, and highlight the revolutionary work FTH is doing to revolutionize mental health treatments using psychedelic-enhanced psycho-therapy.
“We are confident that this state-of-the-art facility and partnership with Field Trip will foster a wealth of innovation for the future of mental health research and therapies, even as we contribute to the regulatory framework that the Government of Jamaica (GOJ) is currently developing,” said Dale Webber, a professor, pro-vice-chancellor and principal at UWI.
Dr. Ben Medrano is psychiatrist and the medical director of Field Trip Health America. In an interview with The Dales Report last week, he shared some of the reasons behind his interest in the field of psychedelic-assisted psychotherapy, as well as some information about depression and the treatment available at Field Trip’s New York location.
For years, momentum has been building toward a brave new world in which psychedelic drugs, such as psilocybin, MDMA, and even LSD become accepted and approved mental health treatments. Although major strides have been made—MDMA is in final-stage clinical trials now—to bring these drugs out of the rave and into the pharmacy, none of them are likely to be available for at least another few years.
Field Trip Health announced Wednesday the closing of a CA$95 million ($76.5 USD million) offering. The raise is one of the largest in the sector’s history, and puts Field Trip’s cash on hand at roughly CA$113.7 million ($91.5 USD million).
Many people have a spiritual experience on psychedelics. How they make meaning of it could be influenced by the metaphysical beliefs of their therapists.
From approving religious exemptions to budgeting for medical research, advocates are hopeful that Biden and a Democratic Congress could mean progress for psilocybin and other therapeutic psychedelics
Psilocybin—the active compound in magic mushrooms—is one of a handful of psychedelic drugs that have shown real clinical promise in the treatment of anxiety, depression, and addiction.
The world’s first legal research and cultivation facility dedicated to psilocybin-producing mushrooms and other plant-based psychedelics has opened in Mona, Jamaica. The facility, Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi, is in partnership with Toronto-based Field Trip Health Ltd. and the University of West Indies (UWI).
A new partnership will see the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.
The University of the West Indies (UWI), Mona, has entered into a partnership with Canadian company Field Trip Ventures Inc., in a new research facility dedicated to psychedelic fungi. Field Trip Natural Products (Ja) Limited Research and Development Laboratory, was formally launched on Tuesday, February 9, 2021, in an event held at the Faculty of Science and Technology at the UWI.
We’re in a shroom boom. One company, Compass Pathways, which plans to offer magic mushroom therapy, listed on the Nasdaq in November with a $1 billion valuation. New funds like Atai are raising hundreds of millions to invest in psychedelics. New companies are listing, new training programmes for therapists are launching, new states are preparing to legalize or decriminalize psychedelics.
Regulators will soon grapple with how to safely administer powerful psychedelics for treating depression and post-traumatic stress disorder.
Researchers say psychedelics like ayahuasca, psilocybin, ketamine, ibogaine and 5-MeO-DMT prove so beneficial to professional athletes because they have the ability to heal. The sacrifice athletes of high-impact sports make to succeed goes beyond the personal and physical. Researchers have found that repeated head blows and concussions can have detrimental long-term effects on the brain—headaches, dizziness, forgetfulness, insomnia, anxiety, depression, aggression, and in some cases, the desire to kill oneself or others.
Master Corporal Scott Atkinson, a 25-year Canadian military veteran, today made an application to Health Canada for an exemption under Section 56 of The Controlled Drugs and Substances Act to access psilocybin-assisted psychotherapy to treat his depression and other mental health conditions resultant from his long and distinguished military career, including active tours in the former Yugoslavia and Afghanistan.
Field Trip Health's Toronto clinic has been selected as a trial site for a new study on MDMA-assisted therapy for eating disorders.
Field Trip expects its Toronto location will be used as a trial site for the Anorexia Nervosa arm of MAPS’ Eating Disorder Study, which has been approved by Health Canada.
Are apps the secret to better psychedelic experiences? Psychedelics advocates love to call substances like ayahuasca an “ancient technology.” Perhaps it’s due to the futuristic visions you see while under the influence; maybe the intensive focus on the present moment feels so new that you assume a crafty engineer has designed the experience. Regardless, cosmonauts know well the sensation of time distortion.
New research suggests that electrophysiological brain signals associated with neural plasticity could help explain the rapid, antidepressant effects of the drug ketamine. The findings, European Neuropsychopharmacology, indicate that ketamine could reverse insensitivity to prediction error in depression.
It has been a tumultuous year for the world at large, with COVID-19 necessitating sweeping changes to ways of life across nearly every geography and domain. Against this challenging backdrop, psychedelic medicine has gained a great deal of traction in 2020. Research and development—including clinical trials—has continued to gain momentum and maturity, while public opinion, regulatory bodies, and mainstream media outlets all appear to be increasingly amenable to the prospect of psychedelic medicines and therapies.
Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the difference between the current available means of obtaining psilocybin. Field Trip Health's Director of Research joins Benzinga to discuss future pathways & opportunities in the space.
Using talk therapy and supervised ketamine sessions to help patients battle anxiety and depression, Field Trip Health is leading the psychedelic-enhanced psychotherapy movement across the United States.
Fran Pulido As an illustrator, you may have never dreamed of seeing your work published in an app. It’s time to overcome this prejudice. In this post, illustrator Fran Pulido explains how to shine in the digital product space — a world constantly demanding visually amazing experiences and talent — and uses the Trip App as a case study for excellence.
Field Trip Health Ltd. has signed a lease to open its first psychedelics-assisted therapy clinic in The Netherlands. This will be the first Field Trip clinic to offer psilocybin treatment, leveraging the fact that mushroom truffles containing psilocybin are not criminalized in The Netherlands.
According to Independent Consultant Mort Goldman, Pharm.D., “Ketamine is relatively short-acting, with an incredibly high level of safety. That’s why it’s a favorite among doctors as a procedural anesthetic.” That’s also why ketamine seems like one of the most reasonable solutions to treating mental and emotional distress in a time when few have access to—or money for—extended psychotherapy sessions that can stretch out for years.
Field Trip Health Ltd., a global leader in the development and delivery of psychedelic therapies, and WHOOP, the human performance company, today announced a partnership whereby Field Trip will be using WHOOP Strap 3.0 to measure the biometric effects of Field Trip’s psychedelic therapies.
As lockdown continues to put conversations about people’s mental health into the spotlight, Los Angeles-based opportunities to partake in psychedelic-assisted therapy are growing.
For many veterans of war, the battle continues even after they’ve returned home from combat. The Veterans Affairs Canada website estimates that up to 10% of their warzone veterans will suffer from PTSD or another mental health affliction, and are 14-19% more likely than the general Canadian population to commit suicide, according to their 2019 Veteran Sucide Report. While both medications and therapeutic interventions are available for this condition, they haven’t proven very effective.
Field Trip Health Ltd, one of the leaders in the development and delivery of psychedelic therapies, announced today that it is in advanced stages of identifying potential sites for Field Trip Health centers to treat people in Oregon with psilocybin therapies following the passage of Measure 109 (“Measure 109” or the “Measure”).
Field Trip Health has shared renderings of their Jamaican facility with Psilocybin Alpha.
Oregon on Wednesday became the first state to legalize the active ingredient in so-called magic mushrooms on an election night that saw more states ease restrictions on drugs across the country.
Field Trip, the leader in the development and delivery of psychedelic therapies, today provided an update on its in-vivo and in-vitro studies on FT-104, its lead drug candidate.
CHICAGO, Oct. 22, 2020 -- Field Trip announces today the opening of their Chicago center. Located at 325 West Huron Street, Suite 603, the Chicago location is the fourth Field Trip Health center to open this year, following Toronto, New York and Los Angeles.
Earlier this week, it was announced that the U.S.-Canada border will remain closed for at least another month amid the spread of COVID-19. Luckily, one of their most useful exports at this particular moment now has a home in the U.S.: the psychedelically enhanced therapy clinic Field Trip Health just opened its first stateside location in Manhattan. The Canadian company opened its flagship clinic in Toronto back in March, calling itself “the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy.” And while the concept of psychedelically enhanced therapy isn’t itself new (you’ve probably heard about Silicon Valley’s obsession with microdosing), the ability of companies like Field Trip or Ember Health to create a sense of normalcy around the practice certainly is.
The Coveteur team investigates Field Trip's take on the aesthetically minded rebranding of psychedelics.
Heroic Hearts Project ("HHP"), an international nonprofit organization that connects military veterans struggling with mental trauma to psychedelic therapies, and Field Trip Health Ltd. (CSE: FTRP) ("Field Trip"), the global leader in the development and delivery of technology-enabled psychedelic therapies, today announced entry into a strategic relationship to increase access to, and awareness of, psychedelic therapies for veterans suffering from mental health disorders such as PTSD.
Field Trip Health Ltd. announces the addition of Andrew Weil, M.D., world-renowned leader and pioneer in the field of integrative medicine, to its medical advisory board. In this role, Dr. Weil will provide Field Trip with medical advice and expertise on healing-oriented approaches to healthcare, as well as guidance on extending the influence and reach of psychedelic therapies.
Welcome to the era of psychedelic stocks. Toronto-based Field Trip Health became the third psychedelic therapy and drug development company to hit the public markets on Tuesday.
TORONTO, Oct. 5, 2020 /PRNewswire/ -- Field Trip Health Ltd. (formerly Newton Energy Corporation) ("Field Trip" or the "Company") (CSE: FTRP), the global leader in the development and delivery of technology-enabled psychedelic therapies, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the "CSE") under the symbol FTRP tomorrow, October 6, 2020.
Field Trip Health Ltd. is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange (the "CSE") under the symbol FTRP tomorrow, October 6, 2020.
After feasting on two new public companies, psychedelics investors will now get a new item on the menu: Field Trip Psychedelics. Field Trip announced its RTO date after market close on Friday. It is preparing to merge with shell company, Newton Energy Corporation (CAN:NTN.H).
The bottom line is that more and more ordinary people who may have never considered such a thing are willing to try psychedelics. And there are more and more companies emerging to help them. One is Field Trip Health, a company offering supervised in-clinic psychedelics experiences, using ketamine for psychotherapy. On their website, anyone can fill out a survey online about who they are and what they are looking for in their own mental health improvement efforts to see if they fit the criteria for psychedelics therapy.
Field Trip Psychedelics Inc. announced Tuesday the successful synthesis of FT-104, a novel compound that is believed to have psychedelic capabilities. The conclusion comes after in-vitro and in-vivo tests confirmed that FT-104 interacts with the 5HT2A receptor, which is the main antagonist targeted by classic psychedelic drugs like LSD, psilocybin and mescaline.
Field Trip Health Ltd. is pleased to announce that it has completed its previously announced reverse take-over of Field Trip Psychedelics Inc. ("FTP") by way of a three-cornered amalgamation (the "Transaction"). The Company will carry on the business of FTP, which is a global leader in the development and delivery of technology-enabled psychedelic therapies. Prior to the closing of the Transaction (the "Closing"), the Company changed its name to "Field Trip Health Ltd." and consolidated the outstanding common shares of the Company (each, a "Share"), on the basis of one post-consolidation Share for every eight pre-consolidation Shares.
Field Trip Psychedelics Inc. announces the launch of its first-ever app, Trip. A first-of-its-kind app and experience, Trip allows people from anywhere in the world to access tools that support self-exploration and consciousness expansion through meditation, breathwork and more.
While I have some reservations about rolling out psychedelic therapy to the masses, I'm also not in favor of restricting access to guides, information, and support for people who might be interested in exploring this avenue of self-help or self-discovery either. In an ideal world, there would ample human guides and assistance for people who are interested in chemically-assisted therapy, but alas, there's still too many taboos (and laws) to make such access readily available and stigma-free. Is an app a sufficiently safe way to provide access instead? Jury's out, but my hunch is no — nor do I think that's what Trip is trying to achieve. And yet here we are — and at least things are moving forward, providing access to support where previously there was little to none that was publicly readily available.
Field Trip Psychedelics Inc. announces it has closed the first tranche of its Series B financing (the "Financing"), raising gross proceeds of $11.0M from a broad base of investors. The Financing was completed through a brokered private placement for which Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc. jointly acted as lead agents.
Field Trip Psychedelics Inc. announces that it is expanding stateside with the opening of a first-of-its-kind clinic in New York City. The clinic, opening under the Company's Field Trip Health brand, exists to help people heal and overcome depression as well as other tough-to-beat mental health challenges through evidence-based, medically supervised psychedelic therapies.
Field Trip offers supervised, in-clinic drug experiences to treat some mental illnesses. But if you want to keep your social distance, an app to stand watch could be the next-best thing.
A mind-expanding injection may be just what the doctor ordered. Psychedelically-enhanced therapy clinic, Field Trip Health, has already begun consulting patients for its new Manhattan location and is set to begin administering medically-supervised ketamine doses as treatment for mental conditions.
Field Trip Health, Inc., the world's first mental wellness company focused on psychedelics and psychedelic-assisted psychotherapy, is opening the first medical centers—first in Toronto, then in New York and LA—dedicated exclusively to the administration of psychedelics, in a “spa-like” setting. So what exactly happens at one of these types of psychedelic therapy clinics? You're going to find out in today's podcast and also discover what kind of biohacks, self-quantification tools, supplements, and more could potentially be combined with plant medicine for enhanced efficacy.
As investors latch onto the promise of psychedelic medicines, clinics and the clinic network management business are poised to take on a major role in the psychedelics investment story.
The idea of psychedelics coming to Canada sounds very exciting however, you won’t be seeing Magic Mushroom shops popping up in your city anytime soon. What you will see are Psychedelic treatment clinics to help those with drug addiction, depression and anxiety disorders.
Field Trip Psychedelics Inc. has launched a new mental wellness program focused on serving “frontliners.” These are individuals suffering from debilitating mental health issues as a result of high-pressure occupations. Think of combat veterans, first responders, and emergency room healthcare workers.
Field Trip Psychedelics Inc., a company doing work in psychedelics and psychedelic-enhanced psychotherapy, announced the launch of Field Trip Basecamp, a long-term program focused on serving individuals suffering from debilitating mental health issues as a result of high-pressure occupations. The immediate focus of the new program will be on “frontliners,” including combat veterans, first responders, emergency room doctors, and other professionals who are regularly exposed to traumatic experiences while on the job.
Javier Hasse, Benzinga Staff Writer, reports about Field Tripping!
Field Trip Psychedelics Inc. announces the launch of the podcast Field Tripping: Epic Trips in Psychedelics with Ronan Levy. The podcast will cover psychedelics, the people that use them, industry trends and frequently asked questions. Field Tripping is available on its website (www.fieldtripping.fm) as well as on Spotify, Apple Podcasts and Google Podcasts.
Despite the fact that most non-COVID medical research and funding has come to a halt during the pandemic, there is one emerging field that is still forging ahead. The legal use of psychedelics to treat severe cases of psychological disorders, including depression, addiction and PTSD, has exploded in popularity among researchers and investors in the past two years and has garnered even more interest in recent months.
Field Trip Psychedelics Inc. ("Field Trip") is pleased to announce its sponsorship of TheraPsil (the "TheraPsil Coalition"), a British Columbia-based non-profit dedicated to facilitating legal access to psilocybin-assisted psychotherapy for terminally-ill Canadians suffering from end-of-life distress.
Field Trip offers virtual breathwork therapy sessions with a dose of ketamine.
Check out NOW Magazine's experience at our Toronto clinic, and how Samantha Edwards experienced our COVID-equipped facility & protocol!
Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic-enhanced treatments to improve mental wellness.
I am talking to Ronan Levy from "Field Trip Health" based in Canada. The company is providing clinics for evidence based legal psychedelic therapies to treat depression. But what I like about "Field Trip Health" is their attitude towards a really dated idea to call some people “sick” or “crazy”. Field Trip Health says, we treat people, not patients. “We are all sick and healthy at the same time. It’s just that some people need more support.” says Ronan.We discuss the design places for a psychedelic treatment should have. Should they look more like a spa? Or a clinic? Or do we need new designs? And do the “ well" need psychedelics to get “better"? Or should we only focus on clinically depressed people? But then again, these concepts and terms don’t work any more. Join me and Ronan talking new psychedelic solutions and why mindfullness is not enough anymore.
In the first of a series of interviews with the trailblazers of the psychedelics industry, Psilocybin Alpha spoke to Ronan Levy: Founder & Executive Chairman of Field Trip Health, Inc.
Company also announces appointment of Nathan Bryson as Chief Science Officer and Pharmaceutical Company Executives Dieter Weinand and Helen Boudreau to the Board of Directors Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, today announced the creation of Field Trip Discovery, the company’s newly formed drug development division.
The aptly named Field Trip Health clinic in Toronto is attempting to change the mental health narrative by providing clients with a ketamine-based therapy to treat depression and anxiety.
Field Trip, a company devoted to alternative psychedelic therapies, opened its first ketamine clinic in Toronto. Up next: Los Angeles and New York City. Special K isn’t just a party drug for ravers anymore.
Welcome to the first edition of Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. MindMed Became the First Psychedelics Company to List Publicly on NEO Stock Exchange, Created New Committee
get in touch
Are you disappointed with the results from other therapies or medications? Is something blocking progress, but you’re not sure what? Find out if psychedelic-assisted psychotherapy is right for you.